Thus, persistent high-lipid treatment not only decreases UCP1 expression but also combines with reduced UCP1 to promote NK cell necroptosis, and it is involved in NASH progression to fibrosis. This evidence concerns the gene UCP1 and metabolic dysfunction-associated steatohepatitis.